Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.

AAQL

WILMINGTON, Del., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:

Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Achillion Pharmaceuticals, Inc. (“Achillion”) (NASDAQ GS: ACHN) common stock in connection with the proposed acquisition of Achillion by Alexion Pharmaceuticals, Inc. (“Alexion”) and Beagle Merger Sub, Inc. (“Merger Sub”) announced on October 16, 2019 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Achillion and its Board of Directors (the “Board”), is captioned Rosenblatt v. Achillion Pharmaceuticals, Inc., Case No. 1:19-cv-02112 (D. Del.).

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at info@rl-legal.com, or at http://rigrodskylong.com/contact-us/

On October 15, 2019, Achillion entered into an agreement and plan of merger (the “Merger Agreement”) with Alexion and Merger Sub.  Pursuant to the terms of the Merger Agreement, shareholders of Achillion will receive $6.30 in cash and one contractual contingent right value per share (the “Proposed Transaction”).

Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a proxy statement (the “Proxy Statement”) filed with the United States Securities and Exchange Commission.  The Complaint alleges that the Proxy Statement omits material information with respect to, among other things, the Company’s financial projections and the analyses performed by Achillion’s financial advisor. The Complaint seeks injunctive and equitable relief and damages on behalf of holders of Achillion common stock. 

If you wish to serve as lead plaintiff, you must move the Court no later than January 28, 2020.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:                                                                                             

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com

Primary Logo